WAM
FRTX

Wealthspire Advisors (Maryland)’s Fresh Tracks Therapeutics, Inc. Common Stock FRTX Stock Holding History

Wealthspire Advisors (Maryland)’s Portfolio FRTX Stock Details FRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-1
Closed – – 2200
2019
Q1 		$0 Buy
+1
New +$335 ﹤0.01% 2619

Other funds holding FRTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FI
Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Wealthspire Advisors (Maryland)'s FRTX Position: Q2 2019 in Review

Wealthspire Advisors (Maryland) sold out of Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) in Q2 2019, closing a stake of 1 share.

Wealthspire Advisors (Maryland) first reported a position in FRTX in Q1 2019 and held it in 1 quarter. The position peaked at $0 in Q1 2019. 22 funds tracked by Wall St. Rank hold FRTX as of Q2 2019.

  • Wealthspire Advisors (Maryland) reported no remaining Fresh Tracks Therapeutics, Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
  • Wealthspire Advisors (Maryland) sold 1 Fresh Tracks Therapeutics, Inc. Common Stock share in Q2 2019.
  • Wealthspire Advisors (Maryland) first reported a position in Fresh Tracks Therapeutics, Inc. Common Stock in Q1 2019 and held it in 1 quarter.
  • Wealthspire Advisors (Maryland)'s Fresh Tracks Therapeutics, Inc. Common Stock position peaked at $0 in Q1 2019.
  • 22 funds tracked by Wall St. Rank held Fresh Tracks Therapeutics, Inc. Common Stock as of Q2 2019.

Based on Wealthspire Advisors (Maryland)'s 13F filing for Q2 2019, filed 12 Aug 2019.